ProfileGDS5678 / 1451033_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 48% 49% 48% 48% 49% 50% 48% 48% 49% 48% 49% 48% 48% 49% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1762748
GSM967853U87-EV human glioblastoma xenograft - Control 23.1565249
GSM967854U87-EV human glioblastoma xenograft - Control 33.1467448
GSM967855U87-EV human glioblastoma xenograft - Control 43.0663848
GSM967856U87-EV human glioblastoma xenograft - Control 53.1126649
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2875950
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.208448
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1204448
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1374149
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.1298548
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1454949
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1010548
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1530648
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.1474349